FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3116504222> ?p ?o ?g. }

• W3116504222 endingPage "1011" @default.
• W3116504222 startingPage "999" @default.
• W3116504222 abstract "Abstract Background Despite numerous chimeric antigen receptor T‐cell (CAR‐T) trials conducted in China, no CAR‐T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR‐T manufacture abroad. Relma‐cel (JWCAR029), an anti‐CD19 product produced with a commercial‐ready process in China, was evaluated in the first prospective, single‐arm, multicenter, pivotal study of CAR‐T therapy conducted under Chinese IND to support an NMPA‐accepted BLA submission in relapsed/refractory (r/r) LBCL (NCT04089215). Methods Patients were randomized to receive either 100 × 10 6 (low dose, n = 27) or 150 × 10 6 (high dose, n = 32) CAR+ T‐cells as a single infusion following lymphodepleting chemotherapy (fludarabine 25 mg/m 2 and cyclophosphamide 250 mg/m 2 daily × 3), and then, monitored for efficacy and safety outcomes and pharmacokinetics. The primary endpoint was ORR at 3 months, as assessed by the investigators. Secondary endpoints included DOR, PFS, OS, and adverse event frequency/severity and cell expansion kinetics. Results As of the data cutoff on 17 June 2020, 68 patients were enrolled, and 59 were treated. Among the 58 efficacy‐evaluable patients, the primary endpoint of 3 month ORR was 60.3% (95% CI, 46.6–73.0), excluding the null hypothesis rate of 20%. Any grade and severe grade CRS occurred in 47.5% and 5.1%, respectively, and any grade and severe grade neurotoxicity events occurred in 20.3% and 5.1%. Conclusions Relma‐cel met the primary endpoint analysis and demonstrated a high rate of durable responses and low rate of CAR‐T‐associated toxicities in patients with r/r LBCL in a multicenter trial supporting regulatory submission in China." @default.
• W3116504222 created "2021-01-05" @default.
• W3116504222 creator A5013936797 @default.
• W3116504222 creator A5017214725 @default.
• W3116504222 creator A5019544133 @default.
• W3116504222 creator A5026009881 @default.
• W3116504222 creator A5026977613 @default.
• W3116504222 creator A5028076162 @default.
• W3116504222 creator A5030040961 @default.
• W3116504222 creator A5034616815 @default.
• W3116504222 creator A5044301848 @default.
• W3116504222 creator A5045048134 @default.
• W3116504222 creator A5045814990 @default.
• W3116504222 creator A5046279416 @default.
• W3116504222 creator A5063194659 @default.
• W3116504222 creator A5066795023 @default.
• W3116504222 creator A5071860246 @default.
• W3116504222 creator A5072097629 @default.
• W3116504222 date "2020-12-31" @default.
• W3116504222 modified "2023-10-13" @default.
• W3116504222 title "Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China" @default.
• W3116504222 cites W1049067418 @default.
• W3116504222 cites W2082708772 @default.
• W3116504222 cites W2118796952 @default.
• W3116504222 cites W2128627731 @default.
• W3116504222 cites W2133201432 @default.
• W3116504222 cites W2133345449 @default.
• W3116504222 cites W2136060045 @default.
• W3116504222 cites W2150587745 @default.
• W3116504222 cites W2342423058 @default.
• W3116504222 cites W2566677727 @default.
• W3116504222 cites W2744261860 @default.
• W3116504222 cites W2760653955 @default.
• W3116504222 cites W2773804840 @default.
• W3116504222 cites W2889646458 @default.
• W3116504222 cites W2891294964 @default.
• W3116504222 cites W2892326722 @default.
• W3116504222 cites W2901318009 @default.
• W3116504222 cites W2921490864 @default.
• W3116504222 cites W2969586911 @default.
• W3116504222 cites W2978437589 @default.
• W3116504222 cites W2986363684 @default.
• W3116504222 cites W2987075075 @default.
• W3116504222 cites W2988836455 @default.
• W3116504222 cites W2989640927 @default.
• W3116504222 cites W3006233208 @default.
• W3116504222 cites W3095855647 @default.
• W3116504222 doi "https://doi.org/10.1002/cam4.3686" @default.
• W3116504222 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7897944" @default.
• W3116504222 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33382529" @default.
• W3116504222 hasPublicationYear "2020" @default.
• W3116504222 type Work @default.
• W3116504222 sameAs 3116504222 @default.
• W3116504222 citedByCount "43" @default.
• W3116504222 countsByYear W31165042222021 @default.
• W3116504222 countsByYear W31165042222022 @default.
• W3116504222 countsByYear W31165042222023 @default.
• W3116504222 crossrefType "journal-article" @default.
• W3116504222 hasAuthorship W3116504222A5013936797 @default.
• W3116504222 hasAuthorship W3116504222A5017214725 @default.
• W3116504222 hasAuthorship W3116504222A5019544133 @default.
• W3116504222 hasAuthorship W3116504222A5026009881 @default.
• W3116504222 hasAuthorship W3116504222A5026977613 @default.
• W3116504222 hasAuthorship W3116504222A5028076162 @default.
• W3116504222 hasAuthorship W3116504222A5030040961 @default.
• W3116504222 hasAuthorship W3116504222A5034616815 @default.
• W3116504222 hasAuthorship W3116504222A5044301848 @default.
• W3116504222 hasAuthorship W3116504222A5045048134 @default.
• W3116504222 hasAuthorship W3116504222A5045814990 @default.
• W3116504222 hasAuthorship W3116504222A5046279416 @default.
• W3116504222 hasAuthorship W3116504222A5063194659 @default.
• W3116504222 hasAuthorship W3116504222A5066795023 @default.
• W3116504222 hasAuthorship W3116504222A5071860246 @default.
• W3116504222 hasAuthorship W3116504222A5072097629 @default.
• W3116504222 hasBestOaLocation W31165042221 @default.
• W3116504222 hasConcept C121332964 @default.
• W3116504222 hasConcept C126322002 @default.
• W3116504222 hasConcept C141071460 @default.
• W3116504222 hasConcept C142424586 @default.
• W3116504222 hasConcept C168563851 @default.
• W3116504222 hasConcept C197934379 @default.
• W3116504222 hasConcept C203092338 @default.
• W3116504222 hasConcept C2776694085 @default.
• W3116504222 hasConcept C2776755627 @default.
• W3116504222 hasConcept C2779263901 @default.
• W3116504222 hasConcept C71924100 @default.
• W3116504222 hasConcept C87355193 @default.
• W3116504222 hasConcept C90924648 @default.
• W3116504222 hasConceptScore W3116504222C121332964 @default.
• W3116504222 hasConceptScore W3116504222C126322002 @default.
• W3116504222 hasConceptScore W3116504222C141071460 @default.
• W3116504222 hasConceptScore W3116504222C142424586 @default.
• W3116504222 hasConceptScore W3116504222C168563851 @default.
• W3116504222 hasConceptScore W3116504222C197934379 @default.
• W3116504222 hasConceptScore W3116504222C203092338 @default.
• W3116504222 hasConceptScore W3116504222C2776694085 @default.
• W3116504222 hasConceptScore W3116504222C2776755627 @default.
• W3116504222 hasConceptScore W3116504222C2779263901 @default.

• next